Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma

17 novembre 2026 mis à jour par: Rong Tao, Fudan University

A Multicenter, Prospective, Phase II, Randomized Study of Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy as First-Line Treatment for Patients With Stage I/II MALT Lymphoma

This is a multicenter, open-label, randomized, controlled phase II study evaluating the efficacy and safety of short-course orelabrutinib induction followed by low-dose involved-site radiotherapy (ISRT) compared with standard-dose ISRT in patients with previously untreated, limited-stage extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).

Aperçu de l'étude

Description détaillée

Eligible patients will be randomized in a 1:1 ratio to either the experimental arm or the control arm. Patients in the experimental arm will receive oral orelabrutinib for 12 weeks followed by 4 Gy ISRT (2 Gy × 2 fractions), while patients in the control arm will receive 24 Gy ISRT (2 Gy × 12 fractions).

The primary endpoint is the 2-year progression-free survival (PFS) rate. Key secondary endpoints include the radiotherapy omission rate, 2-year event-free survival (EFS), complete response (CR) rate, objective response rate (ORR), in-field and out-of-field recurrence rates, safety, and quality of life (QoL).

Type d'étude

Interventionnel

Inscription (Estimé)

272

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200032
        • Fudan University Shanghai Cancer Center
        • Contact:
        • Contact:
          • Numéro de téléphone: 8621-64175590
        • Chercheur principal:
          • Rong Tao, MD&PhD
        • Chercheur principal:
          • Yizhen Liu, MD&PhD
        • Chercheur principal:
          • Xuejun Ma, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age ≥18 years.
  • Histologically confirmed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
  • MALT lymphoma involving, but not limited to, the following sites: orbit, parotid gland, thyroid, Helicobacter pylori (H. pylori)-negative gastric MALT lymphoma, lung, intestine, prostate, and other sites.

For gastric MALT lymphoma, H. pylori negativity must be confirmed by a 13C-urea breath test or gastric mucosal histology. For patients with unknown prior H. pylori status who have previously received H. pylori eradication therapy, serum H. pylori antibody may remain positive. In such cases, at least 1 year must have elapsed since completion of eradication therapy, and repeat gastroscopy and/or breath testing must be negative. Patients with a history of H. pylori infection must have the eradication regimen documented. If t(11;18) testing is available, the result should also be documented for exploratory analysis.

  • Lugano stage I-II disease. Staging will be performed according to the Lugano classification. Limited-stage disease eligible for this study is defined as all known MALT lymphoma lesions being confined to a single organ or paired organs, with or without regional lymph node involvement, and all disease being safely amenable to coverage by limited-field curative-intent involved-site radiotherapy (ISRT).

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

  • Ability to understand and willingness to voluntarily provide written informed consent.

  • Adequate organ function, defined as follows:

    1. Hematologic function: absolute neutrophil count ≥1.0 × 10^9/L, platelet count ≥50 × 10^9/L, and hemoglobin ≥80 g/L.
    2. Hepatic function: total bilirubin ≤1.5 × the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 × ULN, and serum albumin ≥30 g/L.
    3. Renal function: serum creatinine <1.5 × ULN and creatinine clearance ≥50 mL/min, calculated using the standard Cockcroft-Gault formula. For renal impairment caused by tumor compression, creatinine clearance ≥30 mL/min is acceptable.
    4. Coagulation function: unless the participant is receiving anticoagulant therapy and the coagulation parameters (PT/INR and APTT) are within the expected range for the anticoagulant treatment, international normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN.

Exclusion Criteria:

  • Major surgery within 4 weeks before enrollment, except for diagnostic surgery.

  • Uncontrolled concomitant diseases, including cardiovascular or cerebrovascular disease, coagulation disorders, and severe infectious diseases, including but not limited to:

    1. severe acute or chronic infections requiring systemic treatment;
    2. symptomatic congestive heart failure (New York Heart Association class III-IV);
    3. symptomatic or inadequately controlled arrhythmia;
    4. inadequately controlled arterial hypertension despite standard treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
    5. unstable angina;
    6. active peptic ulcer disease or bleeding disorders.
  • Severe concomitant diseases that may interfere with routine treatment.

  • Known active interstitial pneumonia.

  • Viral hepatitis and other active infections:

    1. Active chronic hepatitis B infection, defined as positive hepatitis B virus (HBV) DNA. Patients with latent or prior HBV infection (defined as positive hepatitis B surface antigen [HBsAg] or total hepatitis B core antibody [HBcAb]) may be enrolled if HBV DNA is undetectable at screening. Such patients must be willing to undergo regular HBV DNA monitoring and receive appropriate antiviral therapy as required by the study.
    2. Patients with positive hepatitis C virus (HCV) antibody may participate only if HCV RNA is negative by polymerase chain reaction (PCR).
    3. Active infection with human immunodeficiency virus (HIV) or syphilis.
  • Pregnant or breastfeeding women.

  • Dysphagia or inability to take oral medication on a long-term basis.

  • Patients considered unsuitable for participation in the study by the investigator.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Orelabrutinib + 4 Gy ISRT

Participants will receive oral orelabrutinib for 12 weeks, followed by 4 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 2 fractions. Radiotherapy will be initiated within 4 weeks after completion of orelabrutinib. Response will be assessed after treatment, and additional local radiotherapy or salvage treatment may be administered according to the predefined response-based management strategy.

Orelabrutinib 150 mg orally once daily for 12 weeks. Dose interruption and reduction are permitted according to the protocol-defined toxicity management criteria.

Involved-site radiotherapy (ISRT) at a total dose of 4 Gy, delivered as 2 Gy in 2 fractions, following the ILROG-recommended technical framework for extranodal lymphoma and ISRT. Radiotherapy is initiated within 4 weeks after completion of orelabrutinib treatment.

Comparateur actif: 24 Gy ISRT

Participants will receive 24 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 12 fractions. Radiotherapy will be initiated within 4 weeks after randomization. Patients with inadequate response may receive salvage treatment at the investigator's discretion.

Involved-site radiotherapy (ISRT) at a total dose of 24 Gy, delivered as 2 Gy in 12 fractions. Radiotherapy is initiated within 4 weeks after randomization.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
2-year Progression-Free Survival (PFS) Rate
Délai: 2 years after randomization

Progression-free survival is defined as the time from randomization to the first documented disease progression or death from any cause. Participants without a PFS event at the data cutoff will be censored at the date of the last adequate tumor assessment. Additional 20 Gy radiotherapy administered according to the protocol-defined response-adapted treatment strategy is not considered a PFS event and will not result in censoring.

2 years after randomization

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Radiotherapy Omission Rate
Délai: From randomization through 24 months

The proportion of participants in the experimental arm who receive no additional 20 Gy radiotherapy or other local salvage radiotherapy from randomization through 24 months. The denominator is the intent-to-treat population in the experimental arm, excluding participants who do not receive the planned 4 Gy radiotherapy. Participants who are lost to follow-up, receive radiotherapy outside the protocol, or receive other anti-lymphoma treatment are included in the denominator.

From randomization through 24 months
2-year Event-Free Survival (EFS) Rate
Délai: 2 years after randomization

Event-free survival is defined as the time from randomization to the occurrence of any event, including discontinuation of orelabrutinib because of toxicity, failure to complete 4 Gy radiotherapy, death, disease relapse, disease progression, initiation of a new anti-lymphoma treatment, or additional radiotherapy.

2 years after randomization
Objective Response Rate (ORR)
Délai: Throughout the treatment period, up to 2 years

The proportion of participants who achieve a complete response or partial response according to the study-defined response assessment criteria based on the Lugano 2014 framework, with site-specific adaptations for extranodal MALT lymphoma.

Throughout the treatment period, up to 2 years
Complete Response (CR) Rate
Délai: Throughout the treatment period, up to 2 years

The proportion of participants who achieve a complete response according to the study-defined response assessment criteria based on the Lugano 2014 framework, with site-specific adaptations for extranodal MALT lymphoma.

Throughout the treatment period, up to 2 years
Local Recurrence Rate at the Irradiated Site
Délai: From randomization through 24 months

The proportion of participants who develop disease recurrence at the previously irradiated site during follow-up.

From randomization through 24 months
Incidence of Adverse Events
Délai: up to 2 years

Safety will be assessed by the incidence and severity of adverse events in participants who receive at least one dose of study treatment or at least one radiotherapy treatment. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0.

up to 2 years
Quality of life questionnaire(EORTC QLQ-C30)
Délai: Up to 2 years

evaluate patients' quality of life by questionnaire using EORTC QLQ-C30.There are a total of 30 entries. Among them, items 29 and 30 are divided into seven levels, ranging from 1 to 7 points based on their answer options; The other items are divided into four levels: none, a little, many to many, and are rated directly on a scale of 1 to 4.

Up to 2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chaise d'étude: Rong Tao, MD & PhD, Fudan University
  • Chercheur principal: Xuejun Ma, MD, Fudan University
  • Chercheur principal: Yizhen Liu, MD & PhD, Fudan University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

18 novembre 2026

Achèvement primaire (Estimé)

31 décembre 2031

Achèvement de l'étude (Estimé)

30 juin 2032

Dates d'inscription aux études

Première soumission

11 novembre 2026

Première soumission répondant aux critères de contrôle qualité

17 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner